Catalog No.
PHG54701
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human TOP3A (Lys35-Ser179).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
DNA topoisomerase 3-alpha, TOP3, TOP3A, DNA topoisomerase III alpha
Purification
Purified by antigen affinity column.
Accession
Q13472
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
A noval identification of 4 systemic sclerosis - interstitial lung disease subgroups using principal component analysis-based cluster analysis., PMID:40399864
A Rare Case of Systemic Sclerosis with Topo I Positivity and Anti-Topoisomerase I (Scl-70) Antibody Negativity., PMID:40387758
TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs., PMID:40095530
The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature., PMID:40037059
An overview of small-molecule agents for the treatment of psoriasis., PMID:39832444
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer., PMID:39745368
Evaluating the role of active TGF-β1 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study., PMID:39716300
Disturbed Complement Receptor Expression Pattern of B Cells Is Enhanced by Toll-like Receptor CD180 Ligation in Diffuse Cutaneous Systemic Sclerosis., PMID:39273179
Pathogenic role of anti-nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases., PMID:39248128
Predictors of clinical features in early-onset severe systemic sclerosis: An analysis from a multicenter prospective observational Japanese cohort., PMID:39235167
Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis., PMID:38963343
Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation., PMID:38759301
Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients., PMID:38710779
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer., PMID:38709212
Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review., PMID:38599922
Detection of IgE-autoantibodies to nuclear antigens in patients with systemic sclerosis and analysis of their clinical relevance., PMID:38530662
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis., PMID:38452356
Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis., PMID:38079332
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates., PMID:38016427
Increased binding of anti-dsDNA antibodies to short oligonucleotides modified with topoisomerase I reveals a potential new enzyme function independent from DNA relaxation., PMID:37898816
Could the IgA isotype provide additional information in systemic sclerosis patients? A retrospective study entailing IgA isotyping in a Mediterranean systemic sclerosis cohort., PMID:37812465
Functionally distinct regions of the locus Leishmania major response 15 control IgE or IFNγ level in addition to skin lesions., PMID:37600780
Characterization of a pathway of genomic instability induced by R-loops and its regulation by topoisomerases in E. coli., PMID:37141391
Necessity of HuR/ELAVL1 for the activation-induced cytidine deaminase-dependent decrease in topoisomerase 1 in antibody diversification., PMID:37086201
Autoantibodies against DNA topoisomerase I promote renal allograft rejection by increasing alloreactive T cell responses., PMID:37084848
Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies., PMID:36746531
Bifunctional G-Quadruplex Aptamer Targeting Nucleolin and Topoisomerase 1: Antiproliferative Activity and Synergistic Effect of Conjugated Drugs., PMID:36516871
Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome., PMID:36222553
The impact of sex and anti-topoisomerase I antibodies in systemic sclerosis., PMID:38265957
TOP1 CAD-seq: A protocol to map catalytically engaged topoisomerase 1 in human cells., PMID:35942340
A RADAR method to measure DNA topoisomerase covalent complexes., PMID:35934484
Highly Purified Top1-Bound DNA Fragments., PMID:35704193
R-Loop Detection in Bacteria., PMID:35704183
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor., PMID:35439320
Topoisomerase I inhibitors: Challenges, progress and the road ahead., PMID:35413618
Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA., PMID:34956217
Higher detection of JC polyomavirus in colorectal cancerous tissue after pretreatment with topoisomerase I enzyme; colorectal tissue serves as a JCPyV persistence site., PMID:34592199
Salt-and-Pepper Skin Changes in Systemic Sclerosis., PMID:34289279
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis., PMID:34230031
Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis., PMID:34111525
Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients., PMID:33734322
How Enzymes, Proteins, and Antibodies Recognize Extended DNAs; General Regularities., PMID:33573045
A patent review of topoisomerase I inhibitors (2016-present)., PMID:33475439
Finger sweating levels evaluated by video capillaroscopy system are increased in patients with systemic sclerosis compared to pre-clinical stage patients., PMID:33390568
Helicobacter pylori and Upper Endoscopy in Systemic Sclerosis: A Cross-sectional Study in the Real World., PMID:33347033
Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis., PMID:32911535
Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis., PMID:32840062
Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study., PMID:32662135
Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1)., PMID:32460231
Novel Stable DNA Nanoscale Material and Its Application on Specific Enrichment of DNA., PMID:32250112
For research use only. Not for human or drug use.
